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Abstract
Chronic lymphocytic leukemia (CLL) is a disease with variable clinical outcome. Several prognostic factors such as the
immunoglobulin heavy chain variable genes (IGHV) mutation status are linked to the B-cell receptor (BCR) complex,
supporting a role for triggering the BCR in vivo in the pathogenesis. The miRNA profile upon stimulation and correlation
with IGHV mutation status is however unknown. To evaluate the transcriptional response of peripheral blood CLL cells upon
BCR stimulation in vitro, miRNA and mRNA expression was measured using hybridization arrays and qPCR. We found both
IGHV mutated and unmutated CLL cells to respond with increased expression of MYC and other genes associated with BCR
activation, and a phenotype of cell cycle progression. Genome-wide expression studies showed hsa-miR-132-3p/hsa-miR-
212 miRNA cluster induction associated with a set of downregulated genes, enriched for genes modulated by BCR
activation and amplified by Myc. We conclude that BCR triggering of CLL cells induces a transcriptional response of genes
associated with BCR activation, enhanced cell cycle entry and progression and suggest that part of the transcriptional
profiles linked to IGHV mutation status observed in isolated peripheral blood are not cell intrinsic but rather secondary to in
vivo BCR stimulation.
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Introduction
Chronic lymphocytic leukemia (CLL) patients show a highly
variable clinical course: some patients have an almost normal life
expectancy without need for treatment, while other patients die of
drug-resistant disease within 2 years after initial diagnosis [1].
Currently, clinical consensus recommends not to rely exclusively
on clinical staging systems such as the Rai or Binet score for
prognostic assessment of CLL patients, but to take into account
other prognostic parameters to predict clinical outcome, even in
low stage disease [2]. Besides genetic markers, other markers were
demonstrated to be of prognostic value such as mutation status of
the variable region of the immunoglobulin heavy chain gene
(IGHV) and the expression of CD38, lipoprotein lipase (LPL) and
zeta-chain associated protein kinase 70 kDa, ZAP-70 [3] (reviewed
in [2]). Remarkably, all of them relate to the B-cell receptor (BCR)
directly or indirectly. Additionally, the similarity in BCR structure
and reactivity between some CLL cases suggest that CLL B cells
may typically recognize specific antigens [4,5]. The BCR plays an
important role in the interaction of B cells with the micro-
environment in germinal centers, needed for proliferation and
survival. In CLL, in vivo triggering of the BCR is believed to
contribute to pathogenesis and clinical evolution of the disease [6].
Indeed, antigen recognition by the BCR would result in activation
of transcription factors, such as nuclear factor-kappaB (NFkB)
complex, nuclear factor of activated T cells (NFAT) complex and
FOS [7]. Cross-linking the surface IgM receptor with the use of
anti-IgM antibodies in vitro results in a heterogeneous response
among CLL cases, as assessed by tyrosine phosphorylation, Ca2+
mobilization or even by measuring survival after Ig cross-linking
[8]. The heterogeneous response was found to correlate with
several prognostic indicators of progressive disease, including
CD38, ZAP-70 and IGHV mutation status [8–11]. However,
whether this reflects an intrinsic defect of the BCR signaling
pathway remains unresolved. Controversial data have been
reported on the transcriptional response of CLL upon BCR
stimulation [6,12]. Moreover, micro-RNA expression signatures
correlating with prognostic subgroups have been published [13–
15]. How microRNA expression is affected by BCR triggering and
how it relates to mRNA signatures is at present unknown.
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We report here that both IGHV mutated and unmutated CLL
cells respond to BCR ligation in vitro with prominent MYC
expression and changes in the miRNA profile, typically showing
an induction of the hsa-miR-132-3p/hsa-miR-212 miRNA cluster.
Transcriptome analysis further shows induction of FOS, NFAT5,
DUSP2, EGR1 and ELK1. All these are part of a larger induced
profile of genes associated with cell cycle initiation and progres-
sion, further confirmed phenotypically. This transcriptional
response upon BCR triggering cluster probably supports a MYC
amplified proliferative response that allows CLL cells to multiply
in suitable niches in vivo.
Materials and Methods
Ethics statement
The study protocol was approved by the Ghent University
Hospital Ethical Committee. Patient samples were obtained after
informed consent.
Patients sample collection and characterization
Twenty-one patients newly diagnosed with CLL in Ghent
University Hospital were included in the present study after
informed consent. Peripheral blood mononuclear cells (PBMC)
were isolated on a Lymphoprep (Nycomed, Oslo, Norway) layer,
and contained as expected for the majority CD19+CD5+ CLL cells
(Table S1, median 94%, range 36–99). Cryopreservation did not
compromise functional experiments after thawing. Characteristics
of the patients included are summarized in Table S2. Determi-
nation of IGHV mutation status and intracellular ZAP-70
expression was performed as previously described [16]. Protein
membrane expression was analyzed by flow cytometry after
labeling with anti-CD19 (PE or allophycocyanin, APC), anti-CD3-
fluorescein isothiocyanate, (FITC); both from BD Biosciences, San
Jose´, California, USA) and anti-CXCR4-PE (BD Pharmingen,
San Diego, California, USA). Data acquisition and analysis were
performed using BD FACSDiva software.
Cytogenetic analysis
Detection of copy number aberrations was done either by
fluorescence in situ hybridization (FISH) (cases CLL-1,-4 and 13–
21) or by array comparative genomic hybridization (array-CGH)
(all other cases). FISH was performed as previously described [17]
using the following probes: LSI 13 (RB1)+LSI D13S319 (13q14.3)
(detection of 13q deletion) and LSI TP53 (17p13) (detection of 17p
deletion), both from Abbott Laboratories, Wavre, Belgium, and
BAC clone RP11-241D13 (detection of 11q deletion), BAC PAC
resource center, CHORI, Oakland, CA, USA.
Array-CGH was performed using a 60K SurePrint G3
unselected oligonucleotide array (Agilent Technologies, Amstelv-
een, The Netherlands). For the hybridization of the arrays 200 ng
of tumor DNA and reference DNA were labelled with Cy3 and
Cy5, respectively (BioPrime ArrayCGH Genomic Labeling
System, Invitrogen, Merelbeke, Belgium). Further processing was
done according to the manufacturers’ instructions. Features were
extracted using the feature extraction v10.1.0.0.0 software
program and processed with an in-house developed visualization
software arrayCGHbase (http://medgen.ugent.be/
arrayCGHbase) [18], including circular binary segmentation for
scoring of DNA copy number alterations [19].
Cell culture and BCR stimulation
Cells were cultured as described before [20]. BCR stimulation
was performed as described by Kofler et al. [21] Anti-IgM-
polyacrylamid immunobead (anti-IgM) reagent (Irvine Scientific,
Santa Ana, CA, USA) was added to the PBMC cultures at a
concentration of 100 mg/mL for 3 or 24 hours. Anti-IgA-
immunobeads (anti-IgA, Irvine Scientific) served as a negative
control. In the CD19+ cells (before purification) the annexin
negative fraction remained stable over a period of 24 hours:
average 63% at 3 hours and 66% at 24 hours after initiation of
BCR stimulation.
CLL cell purification was performed after stimulation by
negative depletion using EasySep technology (Stem Cell Technol-
ogies, Vancouver, Canada). The percentage of viable CD19+ cells
was assessed by flow cytometry and was at least 98.2% (data not
shown).
To measure cell cycle progression, stimulated CLL cells were
labelled with CD-19-PE, CD3-FITC and DRAQ5 (Biostatus
Limited, Leicestershire, U.K.) after 48 hours of stimulation and
analyzed by flow cytometry.
Real-time quantitative PCR (qPCR)
Total cellular RNA was extracted using the miRNeasy kit
(Qiagen, Hilden, Germany), cDNA was synthesized and LPL
measured with qPCR as published before [22]. All other genes
were measured using a calibration curve of 8, four-fold dilutions of
cDNA made from stimulated CLL cells. These assays were either
SybrGreen based with primers described before for MYC [23] and
ACTB [24], or probe hydrolysis based using either published
primers and probes (for ABL1 [25]), or Assay-on-DemandH gene
expression assays (Applied Biosystems, for ELK1, NFAT5, FOS,
DUSP2, EGR1, EP400, ZBTB5, CXCR4), used according to the
manufacturer’s instructions. All reactions were performed in
duplicate on a LightCycler 480 (Roche, Basel, Switzerland) or
on ABI Prism 7300 Real Time PCR System (Applied Biosystems,
Foster City, CA, USA). ABL1 and ACTB reference genes were
sufficient to normalize gene expression as assessed with geNorm
software [26]. Expression of selected miRNAs was confirmed on
the same RNA used in the genome-wide miRNA expression
analysis and on an additional patient samples, all without cDNA
amplification before quantification. For normalization, the three
most stable small RNA controls (RNU 48, RNU 24, RNU 44)
were used [27]. All qPCR reactions for microRNAs were
performed in duplicate on a LightCycler 480 or on ABI Prism
7900 HT cycler.
Genome-wide expression analysis
750 ng of total RNA from freshly isolated CLL cells was used
for Illumina microarray analysis in an external facility (ServiceXS,
Leiden, The Netherlands). Quality and integrity of the RNA
samples was analyzed with the Agilent Bioanalyzer (Agilent
Technologies). The Illumina TotalPrep RNA Amplification Kit
(Ambion, Austin, TX, USA) was used to synthesize biotine labeled
cRNA. Biotinylated cRNA (750 ng) was hybridized onto the
HumanHT-12 v3 Expression BeadChip. Illumina’s GenomeStu-
dio v1 software with the default settings was used for Gene
Expression analysis.
The Illumina mRNA expression data were normalized using
quantile normalization from the ‘affy’ package using Rgui
statistical language (www.bioconductor.org). Bead summary data
were log2-transformed and normalized by quantile normalization
using the bead array package [28]. mRNA differential expression
analysis was performed by Rank Product analysis using the
RankProd package [29] in Bioconductor. Pfp (percentage of false
positive predictions) values were calculated from 100 permutations
and a cut-off value of 5% (0.05) pfp was applied to define
differentially expressed genes. Fold change in expression was
miRNA/mRNA Profile after BCR Stimulation in CLL
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e60275
calculated as the average of the expression ratios of IgM
stimulation/IgA stimulation.
Normalized gene expression values were analysed using Gene
Set Enrichment Analysis (according to Subramanian et al. [30])
with phenotype labels representing the different sample subgroups
(i.e. stimulated and unstimulated). The following gene set
collections (version 3.1) were analyzed: Gene Ontology Biological
Process, KEGG and Transcription Factor Targets. Significant
gene set associations were selected based on the FDR q-value
(FDR q,0.05), obtained by 1,000 permutations of phenotype
labels.
Genome wide miRNA expression was measured as described
previously [31]. Briefly, miRNA specific cDNA synthesis for 636
different human miRNAs was followed by pre-amplification by
means of a 14-cycle PCR reaction with a pool of miRNA specific
forward primers and universal reverse primers to increase
detection sensitivity. Finally, pre-amplified miRNA cDNA was
used as input for arrayed qPCR reaction with miRNA specific
hydrolysis probes and forward primer and universal reverse primer
(Applied Biosystems). All reactions were performed on the 7900
HT cycler (Applied Biosystems). Prior to miRNA expression
normalization, Cq-values.35 were excluded from the analysis.
miRNA expression data were normalized using the global mean
[27]. Only miRNAs that were detected in at least 80% of the
samples within one of the defined subgroups were included in the
differential expression analysis. Differentially expressed miRNAs
were identified using the Rank Products algorithm [29] as
described above. Fold change in expression of a miRNA was
calculated as the average of the expression ratios of anti-IgM
stimulation/anti-IgA stimulation.
Correlation mRNA/miRNA
To identify putative functions associated with the miRNAs of
interest, we performed an integrative mRNA – miRNA expression
analysis according to Mestdagh et al. [32]. Briefly, matching
mRNA and miRNA expression levels were correlated using
Spearman’s Rank statistics. For each miRNA, mRNAs were
ranked according to their correlation coefficient and miRNA
associated functions were identified using Gene Set Enrichment
Analysis [33] on the ranked mRNA list. Inferred functions were
uploaded to the miRNA body map webtool (www.
miRNAbodymap.org).
Ingenuity Pathways Analysis software version 9.0 application
2011-07-23, content 2011-05-18 (Ingenuity Systems,Redwood
City, CA) was used to identify and visualize modulated pathways
(http://www.ingenuity.com/products/pathways_analysis.html).
Statistics
All statistical analyses on genome-wide expression data were
performed using the R statistical programming language (version
2.11).
For comparing stimulated versus unstimulated samples, the
Wilcoxon matched pairs test and for comparing unmutated versus
mutated samples the Mann-Whitney U test was applied using the
GraphPad Prism 5 statistical software (GraphPad Software, La
Jolla, CA, USA).
Results
Both IGHV mutated and unmutated CLL cells
transcriptionally respond to B-cell receptor stimulation
Previous studies showed that expression profiles of CLL cells
freshly isolated from peripheral blood show considerable overlap
between unmutated and mutated samples [34,35]. While Her-
ishanu et al. [6] and recently Krysov et al. [36] show that both
IGHV mutated and IGHV unmutated CLL cells transcriptionally
respond to BCR ligation in vitro, other studies reported that IGHV
mutated CLL cells poorly respond to IgM stimulation, in contrast
to IGHV unmutated CLL cells which do respond [12,37–40]. We
stimulated CLL cells with anti-IgM beads or control anti-IgA
beads. After 24 hours of stimulation, both IGHV mutated and
IGHV unmutated CLL cells induced MYC expression to the same
level (Fig. 1A). Similarly, no significant difference was seen in
induction of FOS expression upon 3 hours of BCR stimulation
(Fig. 1B). Collectively, these results show a clear response of CLL
cells to BCR triggering, but no significant difference in stimulation
efficiency between mutated (N=11) and unmutated (N= 10)
cases, measured by FOS or MYC expression. By contrast,
expression of LPL increased on average to levels six times higher
in unmutated compared to mutated cases upon BCR ligation (data
not shown). This illustrates that our samples are inherently
different according to mutational status, since previous reports
[6,41] showed LPL to increase specifically in unmutated CLL cells
upon BCR stimulation.
A peak in MYC expression was reached already after 3 hours
(median about 13-fold induction), but expression remained high
up to 24 hours of stimulation (Fig. 1C). To further analyze the
response we performed kinetic measurement of mRNA expression
of genes downstream of the BCR (transcription factors ELK1,
EGR1, FOS and NFAT5, and of DUSP2, a negative regulator of
ERK) after stimulation of CLL cells. EGR1, FOS and to a lesser
extent ELK1 were induced soon after stimulation, but returned to
control levels within 6 to 24 hours, again without statistical
significant differences between IGHV mutated and IGHV un-
mutated CLL samples. Interestingly, expression of DUSP2, a
negative regulator of ERK that drives expression of these
transcription factors, was induced simultaneously in these samples,
suggesting a negative feedback. In addition, expression of NFAT5
was induced in both IGHV mutated and IGHV unmutated CLL
samples reaching a peak after 3 hours (Fig. 1C), indicating that
also the p38 MAPK pathway was activated in our samples [42].
We did observe that irrespective of mutational status, the
magnitude of induction of these genes within one donor correlated
(data not shown).
Since especially MYC is an amplifier associated with cell cycle
entry in B cells [43], we determined if the stimulated cells did show
phenotypic signs of proliferation. As shown in Fig. S1, DNA
staining revealed that a small fraction of the cells was in S/G2
phase, in IgM stimulated but hardly any in control IgA stimulated
cells. This response was seen both in IGHV mutated and
unmutated CLL cells, in 6 of the 8 samples tested.
B-cell receptor triggering of CLL cells results in a
transcriptional response enriched for genes involved in
proliferation
Genome-wide transcriptome analysis was performed on samples
stimulated for 3 and 24 hours, two time points that are fit to
discriminate the kinetic profiles we observed with the selected
genes observed above in an independent series of samples
(overview of samples in Table S1). Rank-product analysis detected
984 and 1192 differentially expressed genes with an increase in
expression (percentage false positive ,0.05), after 3 and 24 hours
of stimulation respectively, and 1095 (3 hours) and 1190
(24 hours) genes with decreased expression (percentage false
positive ,0.05). Of these, 239 (3 hours) and 164 (24 hours) of
the upregulated genes and 140 (3 hours) and 102 (24 hours) of the
downregulated genes showed a fold change of at least 2 (Table S3).
The most significantly modulated genes with a fold change of 3 or
miRNA/mRNA Profile after BCR Stimulation in CLL
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e60275
more are listed in Table 1. As expected, DUSP2, FOS, EGR1 and
MYC were part of the most prominently upregulated transcripts
3 hours after BCR stimulation, while of these only MYC was more
than 3 fold upregulated 24 hours after stimulation. On the other
hand, ELK1 and NFAT5 were found to be only modestly
upregulated by BCR triggering, scoring below the 2 fold induction
threshold (1.6 and 1.5 respectively, Table S3). The array data are
therefore remarkably in line with the qPCR results in part
obtained in an independent series of samples.
To validate some of these observations in independent samples,
we performed additional stimulation experiments. The increased
expression at the mRNA level translated into secretion of CCL3
and CCL4 by BCR stimulated CLL cells as measured with ELISA
(Fig. S2). Reduction of CXCR4 (confirmed by qPCR on these and
independent samples, as shown in Fig. S3) and CD19 mRNA
expression was accompanied by a reduction of cell surface
expression, as shown in Fig. S4.
To better understand the biological significance of our data we
performed Gene Set Enrichment Analysis using different gene set
collections [30]. We compared stimulated samples to unstimulated
samples, and found in both Gene Ontology Biological Process and
KEGG gene set collections an enrichment for gene sets involved in
cell cycle and metabolic processes. In the Transcription Factor
Targets collection, most enriched sets were genes associated with
MYC activation. (Table S4). As shown in Fig. 2, the profile of the
running enrichment score for the MYC gene set shows a peak in
the ranking region of those genes in expression most correlated to
stimulated samples. This was highly significant both after 3 hours
and 24 hours of stimulation.
B-cell receptor stimulation affects miRNA profiles in B-
CLL cells
In our genome-wide transcriptome analysis after BCR stimu-
lation, we observed clear kinetic modulation of many genes,
suggesting a regulated expression. Given the importance of
miRNAs on gene expression regulation and prior reports on
prognostic relevance of miRNA expression in freshly isolated CLL
cells [13–15], we went on to measure miRNA profiles in pre-
amplified cDNA with a qPCR array assay covering 636 mature
miRNAs, not including hsa-miR-155-5p. We detected 186
miRNAs in BCR stimulated CLL cells, listed in Table S5. Several
of these were reported before by other groups to be relatively
highly expressed in freshly isolated CLL cells [14], such as hsa-
miR-150, also in our samples by far the most abundant
microRNA. To detect modulation of miRNA expression after
BCR stimulation, Rank Products analysis was performed. Table 2
shows up and down-regulated miRNAs (percentage false positive
,0.05). The complete list of detected miRNAs, fold changes (the
average of the expression ratios of anti-IgM stimulation/anti-IgA
stimulation) and percentages false positive are shown in Table S6.
Unsupervised clustering analysis revealed that neither mutational
status nor stimulation was associated with the global miRNA
signature (Fig. S5A and B). However, when clustering was
restricted to the miRNAs hsa-miR-132-3p, hsa-miR-132-5p, hsa-
miR-212, hsa-miR-146a and hsa-miR-155-3p, stimulated samples
grouped almost perfectly together, albeit not according to time of
stimulation nor donor identity (Fig. 3). In addition, this clustering
shows a tight correlation between miR-132 and miR-212
expression. We selected five miRNAs for confirmation with qPCR
without preceding amplification of the cDNA: (hsa-miR-132-3p,
hsa-miR-132-5p, hsa-miR-212 (all significantly upregulated upon
stimulation), hsa-miR-146a (borderline upregulated after
24 hours) and hsa-miR-155-5p (not present in the whole genome
screen but reported before to be relevant in CLL prognostic
signatures [13,14]). As measured by single miRNA specific real-
time PCR shown in Fig. 4, hsa-miR-132-3p, hsa-miR-132-5p and
hsa-miR-212 were strongly upregulated 3 and 24 h after
stimulation, confirming the array data, while the increase of hsa-
miR146a and hsa-miR-155-5p expression was significant after 3 h
but hardly after 24 h of stimulation (p,0.05 and not significant,
respectively). We did not observe a significant difference in
IGHV mutated compared to unmutated cases. Kinetics of the
Figure 1. BCR stimulation of both IGHVmutated and IGHV unmutated CLL cells induces gene expression. Expression of MYC (A) and FOS
(B) in CLL cells stimulated with anti-IgA or anti-IgM beads for 24 hours (MYC) or 3 hours (FOS). Scatter plots show normalized mRNA expression for
IGHV mutated (M,N ; N = 11) and IGHV unmutated cases (U,m; N = 10), horizontal line represent average value. Significant induction of both MYC and
FOS (p,0.05), however not significantly different between IGHV mutated and IGHV unmutated cases. (C) Kinetics of expression of ELK1, NFAT5, FOS,
DUSP2, EGR1 and MYC. Scatter plots show normalized mRNA expression for IGHV mutated (M, N ; N = 4) and IGHV unmutated cases (U, m; N = 4),
horizontal lines represent average values. Significant differences are indicated (*) (p,0.05).
doi:10.1371/journal.pone.0060275.g001
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Table 1. Change in mRNAs expression after 3 hours or 24 hours of BCR stimulation.
3 hours of stimulation 24 hours of stimulation
Upregulated
Gene FC Gene FC
CCL3L1 6.49 CCL4L2 8.74
CCL4L2 6.04 CCL4L1 7.69
DUSP2 6.02 DDIT4 5.59
FOS 5.42 TRIB3 5.18
CKS2 5.34 RGS1 5.08
CCL3 5.27 SLC7A5 4.57
UBTD1 5.21 CCL3 4.14
CCL4L1 5.07 GZMB 4.07
MYC 4.82 MTHFD2 4.02
NR4A3 4.78 CCL3L1 3.84
C13ORF15 4.64 CCL3L3 3.80
FOSB 4.61 MGC4677 3.69
PHLDB1 4.60 MYC 3.42
EGR1 4.58 C20ORF100 3.37
MGC4677 4.49 IGSF3 3.33
NR4A2 4.46 PSAT1 3.27
CCL3L3 4.32 FAM152B 3.26
RCAN1 4.20 CD1C 3.20
SERPINE2 4.02 DBN1 3.20
CHRNA1 3.95 RCAN1 3.19
HOMER1 3.93 MTHFD1L 3.19
TRIB3 3.93 OAS3 3.15
EGR2 3.92 ADM 3.11
MYCN 3.90 LRRC32 3.08
TRK1 3.87 BATF3 3.07
EGR3 3.83 SLC1A5 3.04
LOC143666 3.81
HS.562534 3.71
DDIT4 3.59
RNF19A 3.54
SERTAD1 3.51
PTGER4 3.51
LOC653506 3.49
PIM3 3.49
TRQ1 3.45
CHRNA1 3.42
HS.538259 3.41
GRAMD4 3.39
HS.543887 3.38
RNF19A 3.36
ATF3 3.33
KLF10 3.26
RHOB 3.25
BTG3 3.23
C17ORF91 3.22
MAPK6 3.22
C10ORF54 3.18
miRNA/mRNA Profile after BCR Stimulation in CLL
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miR-132-3p and miR-212 upregulation in an independent series
of samples (Fig. 5) revealed that the peak of induced expression
was reached after 12 hours, and that even after 48 hours,
expression was still clearly induced. Here again, the expression
values measured in IGHV mutated and unmutated CLL were
similar.
Table 1. Cont.
3 hours of stimulation 24 hours of stimulation
Upregulated
Gene FC Gene FC
PDCD1 3.17
CD200 3.13
EIF2AK3 3.07
Downregulated
Gene FC Gene FC
TXNIP 0.20 LTB 0.18
CD79B 0.20 VPREB3 0.22
CXCR4 0.22 CD24 0.23
CYBASC3 0.29 TXNIP 0.28
SEMA4B 0.29 CECR1 0.29
PRICKLE1 0.31 TMEM71 0.30
BCL11A 0.32 ALOX5 0.31
NUAK2 0.33 SNORD13 0.31
FLOT2 0.33 GNG7 0.31
CTDSP2 0.33 CXCR4 0.32
C1ORF162 0.33
TGFBI 0.33
SPOCK2 0.33
Table shows three-fold up- or downregulated genes after 3 or 24 hours of BCR stimulation. Fold change (FC) is indicated, all entries percentage of false positives
,0.0001.
doi:10.1371/journal.pone.0060275.t001
Figure 2. BCR stimulation induces an expression profile enriched for MYC induced genes. Figure shows Gene Set Enrichment Analysis
enrichment plot of MYCMAX_01 gene set from Transcription Factor Targets collection (version 3.1) of data obtained after 3 hours or 24 hours of
stimulation as indicated. Bottom shows location of the genes in MYCMAX_01 set in the ranked list of differentially expressed genes: highest in
unstimulated samples left (red zone) to highest in stimulated samples right (blue zone)). Upper part shows profile the running enrichment score
(green line), showing maximum enrichment score (negative value) in stimulated samples. For both time points, FDR q value was below 0.01.
doi:10.1371/journal.pone.0060275.g002
miRNA/mRNA Profile after BCR Stimulation in CLL
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Integrated miRNA/mRNA induction upon B-cell receptor
stimulation supports cell cycle entry and progression
Pathway analysis demonstrated that many of the differentially
expressed genes after 3 hours of stimulation were involved in BCR
signaling and PI3K signaling (Table S7). As shown in Fig. S6A,
after 3 hours of stimulation, downstream BCR effectors were
upregulated (EGR1, NFAT, ELK1), while expression of upstream
components of the BCR transducing components (CD19, CD79A,
CD79B) and immediate downstream signaling components (LYN,
SYK, VAV1, PI3K components and even ERK1) are already
downmodulated while ERK1-degrading DUSP2 was upregulated.
This wave of modulated expression results after 24 hours of
stimulation in upregulation of NFkB pathway components (Fig.
S6B). As listed in Table S7, 24 hours after stimulation, genes
upregulated were involved in purine metabolism (more than 50
enzymes involved are upregulated, e.g. HPRT1), pyrimidine
metabolism (30 enzymes involved), glycolysis (e.g. all enzymes in
the catabolic pathway from glucose-6-phosphate down to pyru-
vate, including GAPDH) and protein turnover/antigen presenta-
tion (e.g. ubiquitination pathway with many proteasome subunits).
The miRNAs hsa-miR-132-3p and hsa-miR-212 belong to the
same cluster [44], and show considerable overlap in predicted
target genes, according to several algorithms currently in use
(TargetScan or mirDB). Hsa-miR-132-5p is the complementary
strand of the miR-132-3p/miR-132-5p duplex, not definitely
shown to be incorporated in the RNA-induced silencing complex
[45]. As almost no targets of hsa-miR-132-3p/hsa-miR-212 are
experimentally validated, we calculated the correlation between
quantile normalized expression data of each gene with normalized
expression of hsa-miR-132-3p/hsa-miR-212 in the miRNA qPCR
screening in the same sample. Genes showing significant inverse
correlation with the miRNA expression are shown in Table S8.
Some of these are predicted targets of hsa-miR-132-3p/hsa-miR-
212, such as TMEM50B, EP400 and ZBTB5. Other genes
predicted to be targeted by hsa-miR-132-3p/hsa-miR-212 and
significantly inversely correlated in our expression data are CFL2,
ZCCHC11, LRRFIP1, MFSD11, RAD21, EIF4A2, HSBP1,
Table 2. Induction of miRNA expression after 3 or 24 hours of
BCR stimulation.
3 hours of stimulation 24 hours of stimulation
miR FC Pfp miR FC Pfp
hsa-mir-212 17.75 0 hsa-mir-212 20.97 0
hsa-mir-132-3p 7.21 0 hsa-mir-132-3p 12.47 0
hsa-mir-155-3p 2.91 0.021 hsa-mir-155-3p 2.75 0.012
hsa-mir-20a-3p 2.46 0.026
hsa-mir-132-5p 3.12 0.029
hsa-mir-19b-1-5p 2.91 0.035
FC: fold change (the average of the expression ratios of IgM stimulation/IgA
stimulation), Pfp: percentage of false positives is indicated.
doi:10.1371/journal.pone.0060275.t002
Figure 3. A selected set of miR characterizes BCR stimulated CLL cells. Heat-map shows unsupervised clustering of samples (anti-IgM
stimulated black tag, control IgA stimulated grey tag) according to expression of hsa-miR-146a, hsa-miR-155-3p, hsa-miR-132-5p, hsa-miR212 and
hsa-miR-132-3p. Code from blue (22 log2 normalized expression) to red (+2 log2 normalized expression) indicates miR expression levels.
doi:10.1371/journal.pone.0060275.g003
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EID2B and TGFB1. It should be noted that in the set of
correlating genes, hsa-miR targeted genes will be enriched but
correlation in se does not prove targeting. When hsa-miR-132-3p/
hsa-miR-212 target genes predicted by Targetscan are compared
to Kyoto Encyclopedia of Genes and Genomes database (www.
genome.jp/kegg), a significant association with the KEGG BCR
signaling pathway was found, containing upstream components
like CD19, CD79A en CD79B. Possibly, early downregulation of
these genes we observed is in part mediated by hsa-miR-132-3p
and hsa-miR-212.
To evaluate the function of the genes correlating with induced
miRNA after BCR stimulation, we used our in-house developed
web-based algorithm (www.mirnabodymap.org) [32]. The genes
we found to be significantly inversely correlating with an
upregulated miRNA are compared to a database containing
3445 published experimental gene sets. For the hsa-miR-132-3p/
hsa-miR-212 cluster, 26 sets correlated significantly with both
miRNAs (Table S9), of which 12 were related with B cell
progenitor/lymphoma or modulated upon MYC activation,
further suggesting the relevance in MYC amplified cellular
activation, proliferation and oncogenesis.
Discussion
In this study, we show that CLL cells transcriptionally respond
to BCR stimulation with increased expression of MYC, irrespec-
tive of the IGHV mutation status. Genome wide expression
analysis revealed a mRNA/miRNA signature associated with
BCR activation, cell cycle entry and progression.
Considerable overlap exists between the expression profile we
observed and that observed upon BCR triggering by Vallat et al.,
who also demonstrate a functional group of genes associated with
MYC expression [46]. We found matches between the transcrip-
tional program of stimulated CLL cells with that of activated B
cells (upregulated GLA, CTPS, GFI1, NAMPT, CD63, PDIA4/
5/6, ADSL, GART, HPRT1, CCND2, AK2, NME2, GSS,
RPA1, YWHAB/G, downregulated BANK1) [34]. Pathway
analysis showed that in our experiments pathways modulated by
BCR triggering were those known to be downstream of the BCR
Figure 4. miRNAs induced by BCR stimulation of CLL cells. Normalized expression of selected miRNAs in CLL cells stimulated with anti-IgA
(grey columns) or anti-IgM (black columns) beads for 3 or 24 hours (average 6 SD N=13). Induction by anti-IgM is significant for all miRNAs at both
time points (* p,0.05), except for hsa-miR-155-5p after 24 hours.
doi:10.1371/journal.pone.0060275.g004
Figure 5. hsa-miR-132-3p and hsa-miR-212 expression induced by BCR stimulation of CLL cells peaks after 12 hours. Ratio of
normalized expression (IgM stimulated/IgA stimulated) of hsa-miR-132-3p and hsa-miR-212 in CLL cells stimulated for the time as indicated (inset
shows data for 1 hour in enlarged scale). IGHV mutated (M, N; N = 4) and IGHV unmutated cases (U, m; N = 4), horizontal lines represent average
values. Significant induction is indicated (* p,0.05).
doi:10.1371/journal.pone.0060275.g005
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target (SYK/PLCc/NFAT; ITK/ERK1-2/FOS; PI3K/NFkB).
Consequently, many of the genes modulated soon after stimulation
are involved in cell cycle initiation and progression (MYC,
CCND1, CCND2, RBL2, E2F complex) and survival (e.g.
BCL2, FOXO3). Gene Set Enrichment Analysis learned that
stimulated samples were enriched for genes involved in metabo-
lism and cell cycle. In the collection of transcription factor gene
sets, MYC gene sets was the most strongly enriched gene set,
underscoring the importance of this transcriptional activator in
BCR stimulated CLL cells. Burger et al. [47] found a similar
spectrum of upregulated genes, including CCL3/CCL4; EGR2/
EGR3 and MYCN, in CLL cells stimulated by co-culture with
nurse-like cells. After 24 hours of stimulation, many of the genes
found by Burger et al. [47] were also upregulated in our
experiments, together with nucleotide metabolism pathways,
glycolysis and protein turnover, as is expected in cells starting a
program of cell cycle initiation and proliferation. Interestingly, the
profile we detect is similar to that reported by Guarini et al. [12]
for unmutated CLL cells: more than half of the genes reported by
them to be upregulated were also found by us. In addition, the
strongest upregulated genes (more than 3 fold) described by
Guarini et al. [12] were also upregulated, without exception, in
our study. In agreement with them and several other studies
[6,12,47,48], we observed downregulation of CXCR4 (Table 1
and Fig. S3 and S4) correlating with reduced CD62L expression
[38], maybe related to altered migration of stimulated CLL cells
reported before [38,47,48]. Some authors observed a correlation
between markers of progressive disease (mutational status, ZAP-70
expression) and the magnitude of CXCR4 downregulation after
BCR stimulation [38,39]. Moreover, Stamatopoulos et al. [49]
observed reduction in CXCR4 surface expression after contact
with mesenchymal stromal cells only in ZAP70+, not in ZAP702
CLL cells. We did not observe a difference between mutated and
unmutated CLL cells, possibly because in contrast to these authors
we stimulated the mononuclear cell fraction instead of purified
CLL cells, and in addition the anti-IgM beads we use present
immobilized anti-IgM antibodies, which elicit superior BCR
stimulation compared to soluble anti-IgM antibodies which are
rapidly internalized by endocytosis [7,39,50]. The fact that the
transcriptional response is similar in both IGHV mutated and
unmutated CLL does not preclude that protein expression and
activation after BCR ligation is different, as observed by several
authors [50,51]. Taken together, the mRNA expression profiles
match that of BCR activated cells with a prominent signature of
MYC induction, known to promote proliferation and gene
expression in leukemic and other cancer cells [43,52]. It would
be interesting to explore if the similarities in transcriptome
between freshly isolated CLL cells and normal donor CD5+ B
cells still hold after BCR stimulation, to further underscore the
origin of CLL in CD5+ B cell subsets [53].
A unique miRNA signature in freshly isolated CLL cells is
associated with prognostic factors and disease progression in CLL
[13–15]. Notably, expression of hsa-miR-132-3p was found to
correlate with IGHV unmutated status, and included in the
signature of poor prognosis CLL [13–15]. In our experiments, we
found hsa-miR-132-3p to be induced equally well in IGHV
mutated and IGHV unmutated CLL cells, nor was the induction
different in samples with or without 13q14 deletion. The same was
true for hsa-miR-212. Given our transcriptome data, we suggest
that both IGHV mutated and IGHV unmutated CLL cells respond
similarly on BCR triggering, and that the difference observed in
freshly isolated peripheral blood CLL cells reflects a difference in
in vivo triggering of the BCR. As reported by Herishanu et al. [6],
the difference in mRNA profile is mainly restricted to cells
harvested from the blood, and barely present in cells isolated from
lymph nodes. This suggests that in the micro-environment of the
lymph node, BCR triggering occurs for both IGHV mutated and
IGHV unmutated CLL cells, from what we would predict that
miRNA signatures in the lymph node will be different from those
published using CLL cells freshly isolated from peripheral blood.
Besides hsa-miR-132-3p and hsa-miR-212, we detected a
moderate increase in hsa-miR-146a and hsa-miR-155-5p early
after BCR triggering. Interestingly, these miRNAs are upregulated
by NFkB, a pathway we show to be activated after BCR
triggering. In the B cell line Ramos, hsa-miR-155-5p was shown
to be induced following BCR induced activation of a ERK/ELK-
1/FOS pathway [54] which we show to be clearly activated in
CLL cells following BCR triggering.
In our experiments, increased expression of hsa-miR-132-3p
and hsa-miR-212 did correlate with decreased TGFB1, EP400 (a
partner of MYC for transformation [55]), and ZBTB5 expression.
The latter two proteins are known to decrease CDKN1A
expression [56,57] and TGFB1 is an inhibitor of BCR respon-
siveness [58], suggesting a role for hsa-miR-132-3p and hsa-miR-
212 in the complex transcriptional program determining cell cycle
initiation and progression. However, as RB1 activity is blocked by
phosphorylation by the CCND1/CCND2/CDK4 complex, RB1
function will likely decrease to the benefit of E2F complex activity
(reviewed by [59]). In addition, the RB1 homologue RBL2 was
decreased in expression upon BCR triggering. A recent publica-
tion describes an overrepresentation of hsa-miR-132-3p and hsa-
miR-212 in pancreatic cancer and shows that RB1 is a target of
these miRNAs by a luciferase UTR assay [60]. A hypothetical
model of possible miRNA/mRNA interactions and signaling
cascades leading to enhanced BCR response and cell cycle
progression is shown in Fig. S7. The induced miRNAs might
modulate the expression of several proteins and the consequent
effects of MYC induction. We could not prove a causal relation
between increased hsa-miR-132-3p and hsa-miR-212 expression
and reduced TGFB1, EP400 and ZBTB5 expression experimen-
tally in CLL cells, as in our hands transfected miRNA mimics of
these miRNAs did not alter expression of these genes, nor did
miRNA mimics with validated targets used as positive controls
affect mRNA level of their target (e.g. hsa-miR-1 on PTK9
expression). In addition, electroporation of anti-miRs did not affect
gene expression of validated targets (data not shown). Possibly, in
contrast to CLL cell lines, primary CLL cells are not amenable to
exogenous manipulation by hsa-miR mimics or inhibitors in vitro,
and more research will be needed to show a direct causal link
between miRNA expression modulation and target mRNA
expression in these cells.
We conclude that our results point to a transcriptional response
promoting cell cycle in in vitro BCR triggered CLL cells. The
miRNAs induced might shape the response, with prominent
induction of the hsa-miR-132-3p/hsa-miR-212 cluster that targets
several anti-proliferative proteins. However, as reported by others
and confirmed by our unpublished observations, BCR triggering in
vitro is not sufficient to induce proliferation of isolated peripheral
blood CLL cells. Most likely, additional signals that are present in
a suitable micro-environment in vivo, such as the lymph node or
bone marrow, are missing in in vitro culture systems [6]. The
identification of these additional stimuli will be interesting to
discover new therapeutic options in this at present incurable
disease.
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Supporting Information
Figure S1 Cell cycle initiation leads to DNA synthesis in
a fraction of BCR stimulated CLL cells. Flow cytometric
analysis of peripheral blood mononuclear cells stimulated for
48 hours (IgA control stimulated or IgM stimulated) and stained
with CD3-FITC, CD19-PE, and for stoichiometric staining of
DNA, DRAQ5 was used. Plots show lymphocyte scatter gated
(plots A), CD19+/weak CD32 gate cells (plots B), DRAQ5 wideness
versus amplitude, allowing to gate on single cells (plots C), and
DRAQ5 intensity histogram (histograms D). Figures indicate
percentage of CLL cells in S/G2, present in the gated cells. This
example shows results of patient CLL17 (IGHV mutated).
(TIFF)
Figure S2 BCR stimulation of CLL cells induces CCL3
and CCL4 chemokine secretion. Chemokine CCL3 and
CCL4 secretion measured by ELISA in cultures of IgM stimulated
CLL cells. Concentration measured (pg/mL) in function of time
(hours of stimulation) is shown.
(TIFF)
Figure S3 BCR stimulation of CLL cells induces re-
duced CXCR4 gene expression. Kinetics of expression of
CXCR4. Scatter plots show normalized mRNA expression for
IGHV mutated (M, N ;N= 4) and IGHV unmutated cases (U, m;
N= 4), horizontal lines represent average values. Significant
differences are indicated (* p,0.05).
(TIFF)
Figure S4 CXCR4 and CD19 cell surface expression is
reduced after BCR stimulation of CLL cells. (A) Bivariate
dotplots of flow cytometric analysis of CXCR4 versus CD19
expression on PBMC incubated for 24 hours with anti-IgA (left
panel) or anti-IgM beads. Events were gated on live cells, a
representative sample is shown. (B) Expression of surface
membrane CXCR4 in CLL cells stimulated with anti-IgA or
anti-IgM beads for 24 hours. Scatter plots show normalized
expression (ratio’s of mean fluorescence intensity) for IGHV
mutated (M, N ;N=7) and IGHV unmutated cases (U, m; N=7),
horizontal line represent average value. Significant decrease of
CXCR4 expression (p,0.05), however not significantly different
between IGHV mutated and IGHV unmutated cases.
(TIFF)
Figure S5 Unsupervised clustering of samples accord-
ing to miR expression. Heat-map shows unsupervised
clustering of samples according to expression of all miRNAs
detected, highlighted either for mutational status (A, (unmutated
black tag, mutated grey tag) or stimulation (B, (anti-IgM
stimulated black tag, control IgA stimulated grey tag). From blue
over white to red indicates increased miR expression.
(TIF)
Figure S6 Modulation of gene expression of selected
genes upon BCR triggering in CLL cells. Expression of
indicated genes in CLL cells, after 3 hours (A) or 24 hours (B) of
stimulation with anti-IgM beads. Fold change to the expression
level in CLL cells incubated with anti-IgA beads is shown, grey
scale indicate magnitude of fold change for representation
purposes. Arrows represent ‘‘acts on’’, hooks represents ‘‘inhibits’’.
Image constructed using Ingenuity IPAH software.
(TIF)
Figure S7 Cell cycle control genes are modulated upon
BCR stimulation in CLL cells. Expression of indicated genes
in CLL cells, after 24 hours of stimulation with anti-IgM beads.
Fold change to the expression level in CLL cells incubated with
anti-IgA beads is shown, grey scale indicate magnitude of fold
change for representation purposes. Arrows represent ‘‘acts on’’,
hooks represents ‘‘inhibits’’, P: phosphorylated protein. miR-132/
212: hsa-miR-132-3p and hsa-miR-212 miRNA. Hypothetical
model, constructed using Ingenuity IPAH software.
(TIFF)
Table S1 Overview of patient samples used.
(PDF)
Table S2 Patient characteristics.
(PDF)
Table S3 Rank-product analysis for significantly (percentage
false positive ,0.05) up- or downregulated genes (fold change FC
at least 2) in samples stimulated for 3 and 24 hours, ranked
according to increasing percentage false positive.
(PDF)
Table S4 Gene Set Enrichment Analysis of unstimulated versus
stimulated sample categories. Table shows gene sets found
significantly enriched in either sample category from gene set
collections KEGG (shown in black characters), Gene Ontology
Biological Process (shown in blue characters), and Transcription
Factor Targets (shown in red characters), ranked according
normalized enrichment score (NES). False discovery rate (FDR)
q value, based on 1,000 permutations of category labels, was below
0.05. Category indicates sample type gene set is enriched in
(negative scores of NES for stimulated samples).
(PDF)
Table S5 miRNAs detected in BCR stimulated CLL cells.
(PDF)
Table S6 Rank-product analysis of detected miRNA, showing
fold change FC in samples stimulated for 3 and 24 hours, ranked
according to increasing percentage false positive.
(PDF)
Table S7 Canonical pathways associated with modulated genes
after 3 hours or 24 hours of BCR stimulation.
(PDF)
Table S8 Correlation coefficient between gene and hsa-miR-
132-3p or hsa-miR-212 miRNA expression.
(PDF)
Table S9 Gene sets enriched for genes negatively correlating
with hsa-miR-132-3p or hsa-miR-212 miRNA expression.
(PDF)
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